RE:RE:Riovant in plans to sell UC drug to Roche for US$7 BillionIn December 2022, Riovant Sciences and Pfizer formed a subsidiary (Vant Co.) to develop biologicals, specifically the humanized monoclonal antibody targeting TL1A, now being discussed for a US$7 Billion acquisition by Roche.
https://www.sec.gov/Archives/edgar/data/1635088/000114036122043937/brhc10044960_ex99-1.htm
"Our internally discovered antibody against TL1A, could potentially be the first agent to bring biomarker-selected precision medicine to people living with inflammatory bowel disease,” said Mikael Dolsten, Pfizer’s Chief Scientific Officer, President, Worldwide Research, Development and Medical.
https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-form-new-vant-company-focused-developing
Given that Roche is prepared to spend US$7 Billion+ for a biological drug provides more evidence that ONCY's bio-platform biomarker driven precision medicine in pelareorep for use in the treatment of multiple cancers is certainly valued within a range of US$10 Billion to US$15 Billion, as previously detailed.